Recently, we and others have shown that Met blocks HIF-1α expression in some human cell lines derived from aggressive forms of hepatocellular and prostate carcinomas, suggesting a direct involvement of this chromatin-associated protein in the anticancer activity of Met (7). Here, HIF1A is linked to prostate carcinoma.